AstraZeneca, one of the corporations in the race to make a coronavirus vaccine, appears to have encountered an obstacle.

The company has suspended COVID-19 clinical trials worldwide, while investigating an adverse reaction in a test player in the UK.

It is not known how long the closure will last. Sometimes reactions occur that are purely fortuitous, but if they are serious enough, the search is suspended until they can be fully studied.

“We are running to speed up the review of the occasion of marriage to minimize any possible effect on the trial schedule,” AstraZeneca said in a statement released Tuesday night. The company is testing a vaccine originally developed at the University of Oxford. “This is a regime action that deserves to happen whenever there is a prospectively unexplained disease in any of the trials, while under investigation, ensuring that we maintain the integrity of the evidence. “

Disruption represents the first primary setback in what has been a remarkably fluid adventure in the traditionally immediate vaccination effort around the world. That said, large-scale Critical Phase 3 clinical trials are those in which genuine disorders are maximum and likely.

In previous smaller trials, none of the candidate vaccines reported very serious reactions, but in larger trials such as AstraZeneca, rarer reactions would possibly occur, so they are performed before a vaccine is approved.

These large-scale trials divided participants between receiving an active vaccine or a placebo. We do not know what the user received in poor health.

In the United States, in addition to AstraZeneca’s recently pending trial, two large-scale COVID-19 vaccine trials are being conducted, one through Pfizer and BioNTech, a German company, and Moderna, a biotechnology company.

The medical and biotechnological news site STAT, which announced the news of the suspension of the trial, reported that the person’s precise reaction was not known, is expected to recover.

Now the company will have to find out the cause of their reaction, said Dr. William Schaffner, a professor in the Division of Preventive Medicine and Infectious Diseases at Vanderbilt University in Nashville, Tennessee.

“It is very imaginable that according to its protocol, as soon as the occasion occurs, the corporate can suspend the trial and refer the investigation to the Data Safety Monitoring Board, the organization of external experts that then conducts an investigation,” he told me. .

It is imperative to show whether the person’s reaction was caused by the vaccine or by coincidence.

Schaffner presented a hypothetical example of how such a trial can occur. If, for example, one of the participants in the vaccine trial had an attack at the center 3 days after receiving the vaccine and ended up in the hospital, “this would be without delay. an adverse event. ” We don’t know if it’s vaccine-related or not, however, it’s probably the kind of cause that can cause a pause while the Data Security Monitoring Board investigates. “

AstraZeneca in its entirety says:

“As a component of the ongoing global randomized and controlled trials of the Oxford coronavirus vaccine, our popular review procedure was initiated and we voluntarily discontinued vaccination to allow independent review of protection data. This is a regimen action which will have to happen whenever there is . is a prospectively unexplained disease in one of the trials, while it is being studied, ensuring that we maintain the integrity of the trials. In giant trials, the diseases will happen by chance, but will have to be proven independently to determine this carefully. We are working to expedite the single occasion review to minimize any potential effect on the trial schedule. We are committed to ensuring the protection of our constituents and the highest rates of conduct in our trials. ” .